OBI vs. ONC, OPTI, SBTX, HEMO, NSCI, DEST, SNG, OBD, IMM, and BVX
Should you be buying Ondine Biomedical stock or one of its competitors? The main competitors of Ondine Biomedical include Oncimmune (ONC), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Hemogenyx Pharmaceuticals (HEMO), NetScientific (NSCI), Destiny Pharma (DEST), Synairgen (SNG), Oxford BioDynamics (OBD), ImmuPharma (IMM), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry.
Oncimmune (LON:ONC) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
Oncimmune has higher revenue and earnings than Ondine Biomedical. Oncimmune is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncimmune had 3 more articles in the media than Ondine Biomedical. MarketBeat recorded 3 mentions for Oncimmune and 0 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 0.00 equaled Oncimmune'saverage media sentiment score.
35.5% of Oncimmune shares are owned by institutional investors. Comparatively, 7.5% of Ondine Biomedical shares are owned by institutional investors. 28.8% of Oncimmune shares are owned by company insiders. Comparatively, 50.0% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Oncimmune received 67 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
Oncimmune has a net margin of 356.25% compared to Oncimmune's net margin of 0.00%. Oncimmune's return on equity of -144.07% beat Ondine Biomedical's return on equity.
Oncimmune has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
Summary
Oncimmune beats Ondine Biomedical on 8 of the 14 factors compared between the two stocks.
Get Ondine Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ondine Biomedical Competitors List
Related Companies and Tools
